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Abstract
Background: Natural rubber latex allergy is a common and unsolved health problem. Since the avoidance of
exposure is very difficult, immunotherapy is strongly recommended, but before its use in patients, it is essential to
prove the efficacy and safety of extracts.
The aim of the present randomised, double-blind, placebo-controlled clinical trial was to assess the efficacy and
tolerability of latex sublingual immunotherapy in adult patients undergoing permanent latex avoidance.
Methods: Twenty-eight adult latex-allergic patients (5 males and 23 females), with mean age of 39 years (range
24-57) were randomized to receive a commercial latex-sublingual immunotherapy or placebo during one year,
followed by another year of open, active therapy. The following outcomes were measured at baseline and at the
end of first and second year of follow-up: skin prick test, gloves-use score, conjunctival challenge test, total and
specific IgE, basophil activation test, and adverse reactions monitoring.
Results: No significant difference in any of the efficacy in vivo variables was observed between active and placebo
groups at the end of the placebo-controlled phase, nor when each group was compared with their baseline values
at the end of the two year-study. An improvement in the average percentage of basophils activated was observed.
During the induction phase, 4 reactions in the active group and 5 in the placebo group were recorded. During the
maintenance phase, two patients dropped out due to pruritus and to acute dermatitis respectively.
Conclusion: Further studies are needed to evaluate latex-sublingual immunotherapy, since efficacy could not be
demonstrated in adult patients with avoidance of the allergen.
Trial registration number: ACTRN12611000543987
Background
Natural rubber latex (NRL) is an ubiquitous material
and NRL-allergy is a relatively recently considered diag-
nosis as it was first recognised in the late 70s [1,2]. It
mostly affects certain groups of high risk populations
(health care workers, patients with frequent hospitaliza-
tion) but the prevalence of latex sensitisation in general
population is also far from negligible. Moreover, there
has been a recent increasing number of cases of NRL-
allergy in other occupations including hairdressers,
housekeepers, construction workers, food handlers or
security personnel [3,4], probably due to widespread
exposure to latex gloves. Therefore, NRL-allergy repre-
sented a recognised public health concern until correc-
tive measures were adopted (mainly, the substitution of
NRL by other materials or the use of powder-free gloves
in healthcare institutions), resulting in a progressive
decline in the incidence of the disease [5].
The avoidance of NRL is currently recommended to
reduce the risk of allergic symptoms (including life-
threatening reactions) in patients with established
allergy. However, in the ca s eo fN R Lt h i sm e a s u r ei s
clearly insufficient because it is quite difficult to keep
away from the widespread presence of latex in many
products. It is also complicated due to the cross-
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cado, banana or kiwi [6,7], that is mainly due to Hevein
(Hev b 6) sensitisation. Moreover, while long-term
avoidance of natural rubber latex can resolve symptoms,
detectable IgE indicating continued sensitization remains
beyond 5 years [8].
Immunotherapy using a NRL extract could hypotheti-
cally protect these patients from an adverse episode
after accidental contact to NRL. However, although it is
a common sensitization, the availability of different
commercial products with proven efficacy and safety is
still limited. Only a few studies with the appropriate
design (randomized, double-blind and placebo-con-
trolled) have been published regarding the efficacy and
tolerance of specific immunotherapy. In fact, there is
evidence that subcutaneous immunotherapy leads to a
significant improvement in various efficacy parameters
when compared to placebo, but with the drawback of a
high rate of systemic reactions [9,10].
Sublingual administration of NRL-immunotherapy has
also been barely explored in adult patients. Patriarca et
al. [11] showed an improvement in skin and respiratory
symptoms, and also in the conjunctival challenge test,
but this was a non-controlled study. In another open-
label and non-controlled study, Cistero [12] demon-
strated a better tolerability of a rush sublingual immu-
notherapy than with the subcutaneous route, but only
assessed the efficacy measuring a cutaneous response
after 10 weeks. A double-blind, placebo-controlled study
of one-year sublingual immunotherapy was published by
Nettis [13], showing a significant improvement in symp-
toms and medication scores after 12 months of treat-
ment. Finally, a very recent trial suggest that latex SLIT
was more effective than placebo after one-year follow-
up, but only 9 patient completed the study and hence,
results must be taken with prudence [14].
Bearing in mind that the sublingual application is bet-
ter tolerated than the subcutaneous route, more studies
on the long-term effect of this therapy are needed, espe-
cially when such therapy has been available for years.
For this reason, we conducted this independent (spon-
sored by the investigators) randomised, double-blind,
placebo-controlled clinical trial to assess the efficacy and
tolerability after 2 years follow-up of a commercially
available NRL-sublingual immunotherapy in adult
patients undergoing permanent NRL avoidance.
Methods
Design and ethics
This is an independent study which was sponsored by
the investigators and partially funded by public
institutions.
The study was designed in two phases: First, a rando-
mized, double-blind, placebo controlled clinical trial was
carried-out. At the end of the first year, follow-up (T1),
blinding was discontinued and active-treated patients
continued receiving treatment for another additional
year (T2). Those patients who were included in the pla-
cebo group received active therapy for one year in an
open-label manner.
The study was approved by the local Ethic’s Commit-
tee/Independent Review Board as well as by the Spanish
Medicines Agency. The trial was conducted according
to Good Clinical Practice, and therefore, prior to the
enrolment all subjects gave their written informed con-
sent on the basis of verbal and written information and
external monitoring and audit was performed by inde-
pendent investigators. All study procedures are sum-
marised in Table 1.
Patients
Participation in the study was proposed to the 76
patients allergic to NRL registered in the research centre
(Santiago Apostol Hospital, Vitoria-Gasteiz, Spain).
Finally, 28 patients (5 males and 23 females), with mean
age of 39 years (range 24-57 years-old) accepted to par-
ticipate and were included. All the patients were pre-
viously diagnosed as having latex allergy and were
subsequently instructed to avoid exposure to the aller-
gen. The clinical characteristics of the patients are sum-
marized in Table 2.
Inclusion criteria comprised a clinical history of nat-
ural rubber latex allergy (documenting the usual symp-
toms of urticaria, angioedema, rhinitis, conjunctivitis,
asthma or anaphylaxis) or a positive response to the
gloves use test and/or conjunctival test plus positive
prick test to NRL (wheal ≥ 3 × 3 mm). Exclusion criteria
consisted of the usual contraindications for the use of
immunotherapy (severe or uncontrolled asthma, other
immune-mediated diseases, coronary artery disease, or
the concurrent use of beta-blockers or angiotensin-
Table 1 Study procedures
Screening Double
blind
Open
label
Inclusion/exclusion criteria X
Informed consent X
Active treatment XXXXXXX
Placebo XXXX
Skin Prick Tests X XXXXXXX
Glove Use Test XXX
Conjunctival Challenge XXX
IgE XXX
Basophil Activation Test XXX
Adverse events XXXXXXX
Months 0 1 6 12 13 18 24
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Page 2 of 10converting enzyme inhibitors) [15] and the presence of
severe systemic or psychiatric diseases, chronic urticaria
or dermographism. Patients meeting all the eligibility
criteria were randomly allocated to the active immu-
notherapy group or placebo group.
Study treatments
A commercially available sublingual immunotherapy
(SLIT-Latex
®, ALK-Abello, Spain) was assayed in the
trial. The medication for the trial was supplied by the
manufacturer directly to the Department of Pharmacy at
the research centre. It was part of a commercial batch,
but labelled for the trial as specified in the Annex XIII
of Good Manufacturing Practice Guideline. SLIT-Latex
®
is a galenic formulation containing latex allergenic
extract (Hevea brasiliensis), human albumin (except in
vial 4), sodium chloride, phenol, glicerine and water.
The extract is standardised in accordance with the pro-
tein content (SDS-PAGE) and with total protein con-
tent. The higher concentration is 500 mcg protein/mL.
In addition, placebo was prepared by the same manufac-
turers and contained the same composition except the
allergen extract. Both treatments had the same external
appearance, taste and colour. Immunotherapy was admi-
nistered according to manufacturer’s schedule (Table 3).
Patients were carefully instructed to held the drops
under the tongue for 3 minutes before being swallowed.
For safety reasons, according to EAACI, induction phase
was administered at hospital setting under the surveil-
lance of a trained allergologist and patient remained
under observation for at least 30 minutes after each
dose. Successive maintenance doses were self-adminis-
tered at home. Patients attended the hospital every three
months to collect new doses and to return the empty
flasks, which were counted by investigators for the
assessment of compliance.
In vivo tests
Skin prick tests to 4 latex concentrations (4, 20, 100 and
500 μg) were performed in duplicate in each study visit.
Positive (histamine hydrochloride 10 mg/ml) and nega-
tive (saline solution) controls were also included in each
test. The areas of the papullae were transferred onto
paper and subsequently measured by planimetry using
specific software [16]. The mean of the areas of the
papullae were calculated for both groups, active and pla-
cebo. For comparing the results of prick test, before and
after immunotherapy, the cutaneous tolerance index
(CTI) was calculated. This index is the factor by which it
is necessary to multiply the dose of the extract to obtain
a similar cutaneous response and estimates the greater or
smaller cutaneous sensitivity of one group in relation to
the other group. When it is used to evaluate whether
changes are observed in a group of patients, a CTI higher
than 1 indicates a reduction in the cutaneous response.
Glove Use Test (GUT) was carried out with high con-
tent latex gloves (Non-sterile Aachen
®, Spain) and with
vinyl 100% latex-free gloves (Torval
®, China). Patients
were protected with glasses and a latex-free mask in
order to avoid concurrent eye and/or inhalative exposure.
Patients wore one type of glove (latex or vinyl) on each
hand for 5, 15, and 30 minutes, separated by an interval
of 20 minutes. Symptoms (pruritus, erythema, wheals)
were scored (0 = absent; 1 = mild; 2 = moderate; 3 =
severe) as previously described [17]. The test was stopped
when a symptom score of 5 was reached. Results are
expressed as the estimated time to achieve five points.
Conjunctival Challenge Test (CCT) was performed
applying five increasing concentrations of a NRL extract
(0.08 - 0.4 - 2 - 10 and 50 mg/ml), separated by 15 min-
ute intervals. The test was carried out by placing a drop
of the lower dose on the inferior conjunctival fornix of
t h er i g h te y ea n do n ec o n t r o ls a l i n es o l u t i o nd r o po n
the left eye. The test was considered negative if no reac-
tion was seen after 15 minutes, and then the next con-
centration was added to the right eye. Symptoms of
hyperaemia, chemosis, epiphora, pruritus, sneezes, and
nasal congestion were scored as previously described
[18] (0 = absent; 1 = mild; 2 = moderate; 3 = severe).
The test was stopped when a symptom score of 5 was
reached. Results are expressed as the estimated concen-
tration to achieve five points.
Table 2 Clinical and molecular features of patients
recruited
Active group Placebo group
Nr. PATIENTS
Total 14 14
PROFFESION
Health care 9 8
Other 5 6
SYMPTOMS
Urticaria 10 11
Rhinoconjunctivitis 10 9
Asthma 7 1
Anaphylaxis 4 2
OTHER SENSITIZATIONS
Food allergy 7 5
Allergy to aeroallergens 4 6
Mites 4 4
Pollens 2 6
Moulds 2 0
Epithelia 0 2
SPECIFIC IgE
Median IgE-k82 7.5 kU/L 1.8 kU/L
Median IgE Hev b 5 5.6 kU/L 0.0 kU/L
Median IgE Hev b 6 1.5 kU/L 0.4 kU/L
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Specific IgE to natural rubber latex (k82) and to recom-
binant allergens (rHev b 1, rHev b 3, rHev b 5, rHev b
6,01; rHev b 8) were measured by a standard system
based on fluorescent solid phase enzyme immunoassay
(CAP-FEIA
®, Phadia, Sweden).
Basophil Activation Test (BAT): The percentage of
basophils that expresses CD63 as an activation marker
after in vitro s t i m u l a t i o nw i t ha na l l e r g e ne x t r a c to f
latex was determined by flow cytometry, following dou-
ble labelling with the monoclonal antibodies anti-CD63-
PE and anti-IgE FITC. Aqueous sterile filtered standar-
dised extracts of latex devoid of any preservatives at
final concentrations of 0.125 and 0.03125 mg protein/ml
(BIAL-Aristegui, Bilbao, Spain) were used.
For comparison between BAT results at different
times, the mean of the percentage of basophils that
expressed CD63 after in vitro stimulation with an aller-
gen extract of latex at final concentrations of 0.125 and
0.03125 mg protein/ml were calculated.
Safety
Since the induction phase was carried out in the hospi-
tal and the patients remained under direct medical sur-
veillance during 30 minutes after treatment
administration, immediate adverse events were directly
recorded in the Case Report Form. In addition, heart
rate, arterial pressure and peak-flow measurement were
measured before and after the administration of a dose.
During the maintenance phase, patients were instructed
to annotate any inconvenience on a diary card. Safety
was monitored by the investigators each study visit, and
in addition, the patient always had the opportunity to
contact the allergologist or to attend the emergency
room in case of severe adverse reactions. Adverse
reactions were classified according to European Acad-
e m yo fA l l e r g y ,A s t h m aa n dC l i n i c a lI m m u n o l o g y
(EAACI) recommendations [14].
Statistical methods
Changes in cutaneous reactivity by skin prick test were
analysed using a parallel lines assay [19] and the ALASA
CRS PLA software (Madrid, Spain) [16]. The differences
were expressed using the Cutaneous Tolerance Index
(CTI), calculated as above was described. The CTI is
expressed with the 95% and 99% confidence intervals.
When CTI is applied across groups, it estimates the
greater or smaller cutaneous sensitivity of one group in
relation to the other group. When it is used to evaluate
whether changes are observed in a group of patients, a
CTI higher than 1 indicates a reduction in the cuta-
neous response.
For the evaluation of Glove Use Test, a linear regres-
sion line symptom’s score/time was calculated in each
patient to individually estimate the time to reach five
points. In a similar procedure, for the evaluation of
Conjunctival Challenge Test, the individual linear
regression symptom’s score/concentration was calcu-
lated to individually estimate the concentration neces-
sary to reach five points.
Comparisons between groups and within groups were
performed through the non-parametric Mann-Whitney’s
and Wilcoxon’s tests, respectively. Significance was set
at p < 0.05.
Results
Twenty seven out of the 28 patients initially enrolled
completed the first year of follow-up. The remaining
subject dropped out due to personal reasons not related
with the trial. At the end of the double-blind trial, one
Table 3 Treatment schedule of Sublingual Latex Immunotherapy: Concentration of vials and build-up dosing
Day Flask Concentration (μg/ml) Nr.
drops
Dose administered
(μg)
Cumulative dose
(μg)
Total/day (μg)
1 (0) 5.10
-8 1
10
2.10
-9
2.10
-8
2.10
-9
2.10
-8
(1) 5.10
-5 1
10
2.10
-6
2.10
-5
2.10
-6
2.10
-5
2.10
-5
2 (2) 5.10
-2 1
10
0.002
0.02
0.002
0.022
(3) 5 1
10
0.2
2
0.222
2.222
2.2
3 (4) 500 1
2
3
4
10
20
40
60
80
200
22.2
62.2
122.2
202.2
402.2
400
4 (4) 500 25 500 902.2 500
Maintenance
5 (4) 500 2/24 h. 40 40
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Page 4 of 10patient in the active group and 4 patients in the placebo
group declined to participate in the subsequent open-
label phase with active treatment. During the second
year, another three patients dropped out and finally 19
patients completed 2 years of follow-up (Figure 1). In
summary, 11 patients received active immunotherapy
for 2 years and 22 patients received active immunother-
apy for one year (14 during the first year and 8 during
the second year).
Before treatment was begun, cutaneous sensitivity to
NRL in the active group was similar to that in the pla-
cebo group (CTI 2.45; 95%CI: 0.59-13.95). After the
one-year double-blind period, there was no significant
variation in cutaneous sensitivity to the allergen with
the active immunotherapy (3.11; 95%CI: 0.87-15.26).
When intra-group CTIs (Figure 2) were evaluated,
comparing T1 and T2 results with the initial value (T0),
in the active group no difference was seen after one year
(0.88; 95%CI: 0.33-2.37) or 2 years active immunother-
apy (1.32; 95%CI: 0.66-2.63). In the placebo group, no
differences were observed after the first year of placebo
therapy (1.71; 95%CI: 0.92-3.18) nor after the 2 years of
follow-up, the last under active immunotherapy (1.45;
95%CI: 0.52-4.05). When only the year of active immu-
notherapy was evaluated in the placebo group (T2/T1
comparison), also no differences were found (0.65; 95%
CI: 0.18-2.35).
At time of diagnosis, all but one patient were posi-
tive to at least one of the challenge tests. This patient
fulfilled inclusion criteria because had suffered from
symptoms after contact with latex in the last two
years. GUT was positive in 24/28 and CCT was posi-
tive in 26/28 patients. During the follow-up, no
improvement in either GUT or CCT response could
be observed, and the number of patients improving
was similar to the number of patients worsening in
both the Active or Placebo group (Table 4). There
were no differences in the mean of the NRL-concen-
tration in CCT to obtain 5 points of symptoms (CCT-
5) between active (16.6 mg/ml; 95%CI 5.8-27.3) and
placebo (24.4 mg/ml; 95%CI 4.2- 44.5) groups in T0. A
non significant improvement was observed comparing
the mean CCT-5 in T0 and T1 both in Active (mean
CCT-5 at T1: 27.1 mg/ml; 95% CI 5.8-48.3) and in Pla-
cebo groups (mean CCT-5 at T1: 35.2 mg/ml; 95% CI
0-71.9). No statistical differences were observed
between Active and Placebo at T1.
There were no differences in the mean of the time in
minutes in contact to the glove in GUT to obtain 5
points of symptoms (GUT-5) between Active (23.8 min-
utes; 95%CI: 1 - 52) and placebo (28.6 minutes; 95%CI:
4.3 - 52.8) groups in T0. An improvement was observed
comparing the mean GUT-5 in T0 and T1 only in Pla-
cebo group (mean GUT-5 at T1: 64.0 minutes; 95% CI:
0.1 - 130.4); in Active group the mean of GUT-5 at T1
(18.5 minutes; 95% CI: 8.7 - 28.3) got worsen. No statis-
tical differences were observed between Active and Pla-
cebo at T1.
Among the 28 enrolled subjects, at time of diagnosis
27 presented a positive level to IgE-k82, 15 to IgE-Hev
b 5 and 19 patients were positive to IgE-Hev b 6. Only
2 patients were positive to the other recombinant aller-
gen tested (IgE-Hev b 1, IgE-Hev b 3, IgE-Hev b 8).
No changes were observed in specific IgE levels (k82,
Hev b 5, Hev b 6) comparing active with placebo groups
at any investigational time (T0, T1 or T2). A slight but
not significant increase followed by a decline to baseline
values throughout treatment was observed in the Active
group (Figure 3). In the Placebo group, no changes were
seen during the first year, but a non-significant increase
was observed after the second year with active therapy,
similar to the other group.
At the beginning of the study, BAT was positive in 14/
14 patients in the Active group and in 12/14 in the Pla-
cebo group. No changes were observed at the end of the
double-blind trial, when 12/14 and 12/13 patients,
respectively, proved positive. However, at the end of fol-
low up, a clear improvement was demonstrated in both
Active group (6/11 positive subjects; 4 negative and 1
not evaluable) and in Placebo group (after only one year
of active immunotherapy, 4/8 positive patients, 3/8
negative and 1 not evaluable). No statistical differences
were observed comparing the mean of percentage of
basophils activated with the NRL concentration of 0.03
mg/mL between active and placebo groups at T1 (data
not shown).
Figure 1 Allocation of patients to treatment group and study phases.
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Page 5 of 10The average percentage of basophils activated
decreased in the Active group after the 2 years of treat-
ment, and also in the Placebo group only after the sec-
ond year of active treatment. Also, the percentage of
patients in whom BAT fell was higher according to the
number of years of active treatment (Table 5).
No severe adverse events occurred and all the patients
reached the maximum dose. A total of 9 mild adverse
events were recorded during the induction phase, 5 in
four patients from the Placebo group during the buid-
up of the placebo treatment (1 conjunctivitis, 1 rhinor-
rhoea, 1 pruritus, 1 dyspnoea, 1 tongue pruritus)
occurred in the first doses of the immunotherapy; and 4
reactions in 4 patients from the Active group, that
appeared when high doses of an allergen extract of latex
were reached (1 tongue pruritus, 3 rhinoconjunctivitis).
The build-up schedule was modified only in one patient
corresponding to the Placebo group.
During the maintenance phase, one patient was with-
drawn after the first year of active treatment due to
cutaneous pruritus over the previous months. Another
patient who switched from placebo to active treatment
in the second year of the study, suffered from an out-
break of acute dermatitis in the feet after one week of
maintenance, and was then dropped from the study.
Discussion
The increase in latex allergy incidence observed in the
80s was associated with the 25-fold increase in the use
of latex gloves in order to prevent the transmission of
increasing incidence of transmission viral diseases
(mainly HIV, BHV and CHV) [20]. Although natural
rubber latex exposure dramatically diminished in the
sanitary environment, thanks to its functional properties,
latex is the basis for manufacturing a large variety of
products and there is even now a widespread distribu-
tion of latex-containing products in other professional
(hairdressers, food-service workers, cleaning workers,
police officers) or personnel settings, including sports
[21]. Therefore, due to the difficulties to completely
avoid the allergen, it is recommended the specific desen-
sitization of those patients, mainly with potential occu-
pational exposure, because it would be expected that in
the case of accidental exposure, the reaction would be
less severe than in non-hyposensitized allergic patients.
Sublingual administration can be an advantageous
alternative to the classical subcutaneous immunother-
apy, its efficacy and safety should be distinctively
demonstrated for each allergen. In this study, a com-
mercially available sublingual immunotherapy with
Figure 2 Results of Cutaneous Tolerance Index (CTI) in Active and Placebo groups during the two years of study.
Table 4 Evolution of Glove Use Test (GUT) and
Conjunctival Challenge Test (CCT) tests during follow-up
period
GUT CCT
Active Placebo Active Placebo
T0
Nr. Positives/Total 13/14 11/14 14/14 12/14
T1
Nr.Improving/Total 6/14 4/12 7/14 6/13
Nr.Worsening/Total 2/14 5/12 2/14 2/13
Nr. No changes/Total 6/14 3/12 5/14 5/13
T2
Nr.Improving/Total 3/11 2/9# 7/11 5/8#
Nr.Worsening/Total 6/11 4/9# 1/11 0/8#
Nr. No changes/Total 2/11 3/9# 3/11 3/8#
# Comparing T2 with T1, after 1 year of active therapy.
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through an appropriate randomized and blinded design.
It must be highlighted that this was an independent
clinical trial, founded only by public funds. Nevertheless,
the study was carried out according with Good Clinical
Practice guidelines, including appropriate monitorization
by external investigators.
Randomized, controlled and blind clinical trials are the
standard for the evaluation of new medicines. However,
since the sublingual therapy was commercially available,
A 
B 
Figure 3 A. Mean IgE-k82 (black square), IgE-rHev b 5 (black circle), and IgE rHev b 6 (black triangle), during the 2-years follow-up, in
active group; B. Mean IgE-k82 (black square), IgE-rHev b 5 (black circle), and IgE rHev b 6 (black triangle), during the 2-years follow-
up, in placebo group.
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sidered not ethically appropriate. In consequence, a
combined design was chosen, comprising a first year of
double-blind placebo-controlled treatment followed by
an additional year as open-label follow-up. This design
allowed the assessment of both, the comparison of
active and control groups during the first year as well as
evaluation of the evolution of the active therapy during
2 years.
A common difficulty in clinical research is the enroll-
ment of patients. In our study, all the latex allergic
patients diagnosed at the research centre were directly
contacted to requested their participation in the trial.
The number of patients finally evaluated can be consid-
ered to be truly representative and it is noteworthy that
more than 1/3 of the total population of NRL allergic
patients registered in the Health Area finally participated
in the study. However, the number of withdrawals in the
switch from the double-blind to the open-label phase
was higher than expected. This can be partly attributed
to a subjective perception of the lack of efficacy and
partly to the low frequency of symptoms and subjective
feeling of not needing treatment. In spite of two patients
who abandoned the study because they suffered an
acute recurrence of skin symptoms (both had a history
of former atopic dermatitis). The majority of the
patients were occupationally exposed to latex before the
diagnosis, and 60% of them were health-care profes-
sionals. The distribution of health-care workers between
active and placebo groups was well-balanced. Demo-
graphic and clinical features and baseline characteristics
were well matched, except in the number of patients
who suffered from asthma, which were predominantly
allocated to the active group. Also, there was a differ-
ence in the NRL specific IgE, which was also higher in
the active group.
Regarding the allergenic distribution, all the patients
had a uniform pattern of latex sensitization, and recog-
nized predominantly Hev b 5 and Hev b 6 allergens that
are considered major allergens in patients occupationally
exposed to latex [22]. Only 2 patients were sensitized to
Hev b 1, an allergen linked to patients with spina bifida
and repeated surgical procedures. The individual assess-
ment of those cases showed that they had not a
response to therapy, which could be partly attributed to
the fact that Hev b 1 was not present in the composi-
tion of the extract used in the immunotherapy, accord-
ing to manufacturer’s information.
The study also suffered from one of the usual weak-
ness in clinical trials in allergy comparing with other
diseases, namely the lack of a single, objective, reliable
and easily measurable variable to evaluate the efficacy of
treatment. Therefore, in the case of immunotherapy stu-
dies, the analysis of efficacy usually relies on several
clinical or analytical variables, self-questionnaires, mea-
surements of quality of life, etc. Moreover, the particular
case of latex immunotherapy has an additional difficulty
comparing with clinical trials with other allergens since
some of the commonly used variables (symptoms score,
consumption of medication) were not useful because the
patients avoid contact with the allergen and these para-
meters are thus not measurable. Although other authors
[12] have used a clinical score to evaluate the efficacy of
a latex extract, the use of such evaluation cannot be
considered appropriate when no allergenic exposure is
expected. However, in our study, this difficulty was
overcome by the use of several in vivo (skin prick test,
CCT, GUT) and in vitro tests (determination of specific
IgE and BAT) to evaluate the therapeutic response to
immunotherapy.
The main result of the study was the lack of signifi-
cant differences in the majority of the variables studied,
and in none of the different comparisons performed:
comparison between groups (active versus placebo
group after one year of treatment) and within groups
after one or two years of active treatment.
The only variable with a statistically significant differ-
ence was a fall in the percentage of basophils activated
in contact with NRL in BAT in the active group versus
placebo. Other published studies showed a significant
decreased percentage of basophils activated after 4
months of oral immunotherapy to peanut, analysing the
result of one concentration (10 μg/ml) of the allergen
used in the test [23]. However, the clinical significance
of this finding remains unclear because no clear rela-
tionship exist with the remaining variables studied. In
the future, more studies are needed that explore this
finding.
The evolution of specific IgE showed an initial
increase only seen when the patients received the active
treatment, and a subsequent decrease in the second year
of treatment in the active group, consistent with a tran-
sitory immunological effect of the immunotherapy.
Surprisingly, a previous not controlled study [11] with
the same extract and in a similar number of patients
Table 5 Results of Basophil Activation Test (BAT) in all
the patients
N. of years in active treatment
012
fall 2 11 8
raise 11 10 2
total 13 21 10
% that fall 15% 52% 80%
Number and percentage of the patients whose BAT results fell or rose after T0
(patients from the Placebo group at T1), 1 year (the sum of the patients from
the Placebo group at T2 and Active group at T1), or 2 years of active
treatment (Active group at T2).
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Page 8 of 10(26) shows an improvement in glove-use test and rub-
bing test after only 10 weeks of treatment (4-day
build-up phase followed by 9 weeks of maintenance).
However, likewise to our trial, no change was detected
by the parallel line assay for prick test. Another similar
clinical [12] using the same extract in 35 patients
found an improvement in symptom and medication
scores in active group after12 months of treatment.
The study was well-designed, but certain aspects
require further clarification since no data were pro-
vided as to the occupation of the patients and the
number of patients exposed to latex. Furthermore, the
differences found in the study could be explained by
the different exposure to NRL in both groups. In view
of the low incidence of symptoms of NRL-allergic
patients when they are diagnosed, we desisted from
considering symptoms and medication scores as a vari-
able. However, contrarily to our results, the authors
did find a significant difference in the glove use test
score between placebo and active group after 12
months of treatment.
A low frequency of adverse effects was recorded dur-
ing the build-up phase of the treatment and all the
patients reached the high dose. However, two patients
had to drop out the study because of cutaneous symp-
toms that appeared during the maintenance phase.
Those findings are awfully different to the reported in a
very recent trial with 12 patients, in which 3 patients
dropped out due to severe adverse events during induc-
tion phase [13]. Nevertheless, the explanation can rely
in the fact that 2 of such patients had a history of ana-
phylactic events to chesnut and it is well known the
association of latex sensitization with fruit allergy,
including nuts.
Bearing in mind how well the treatment was tolerated,
the lack of efficacy could be explained by the low dose
used during the maintenance phase of the treatment.
During the build-up phase, a dose of 500 mcg was
reached by the fourth day, but from then on, a dose of
only 40 mcg/d was administered during the rest of the
treatment. It could thus be hypothesized that a greater
dose should be used during the maintenance phase,
especially when a long-term effect is desired. The low
size of the sample, and the difference in the distribution
of the patients that had suffered NRL-triggered asthma
and the means of specific IgE to NRL between active
and placebo group could also affect the absence of
demonstrated efficacy.
Conclusion
In conclusion, further studies are needed to evaluate the
efficacy of the assayed NRL-sublingual immunotherapy.
Specifically, use of a higher dose in the maintenance
phase should be explored, since the maximum dose of
the build-up phase has shown good tolerance. However,
this present study raises some doubts as to the applic-
ability of this immunotherapy to those patients who can
avoid contact with latex.
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